Trial intelligence / Profile preview

Enhanced Systemic and Local Therapy in Oligometastatic Prostate Cancer

NCT05212857Phase 2Unknown

Sponsor
Fudan University
Start
Apr 2022
Primary completion
Feb 2024
Modality
Orthosteric Ligands
Countries
1
01

Overview

A Phase 2 trial of Abiraterone Acetate Tablets (I), apalutamide, enzalutamide in prostate cancer (PCa), sponsored by Fudan University. Status: unknown.

02

Drugs

Abiraterone Acetate Tablets (I)apalutamideenzalutamide
03

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on NCT05212857.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05212857.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call